These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36638768)

  • 21. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    Simone M; Lucisano G; Guerra T; Paolicelli D; Rocca MA; Brescia Morra V; Patti F; Annovazzi P; Gasperini C; De Luca G; Ferraro D; Margari L; Granella F; Pozzilli C; Romano S; Perini P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Lugaresi A; Portaccio E; Filippi M; Amato MP; Iaffaldano P;
    J Neurol; 2024 Oct; 271(10):6782-6790. PubMed ID: 39179712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late onset multiple sclerosis: concerns in aging patients.
    Lotti CBC; Oliveira ASB; Bichuetti DB; Castro I; Oliveira EML
    Arq Neuropsiquiatr; 2017 Jul; 75(7):451-456. PubMed ID: 28746432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Butler Pagnotti R; Hua LH; Miller JB
    Mult Scler; 2022 May; 28(6):933-941. PubMed ID: 34410177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older-Onset Multiple Sclerosis.
    Knowles S; Middleton R; Cooze B; Farkas I; Leung YY; Allen K; Winslade M; Owen DRJ; Magliozzi R; Reynolds R; Neal JW; Pearson O; Nicholas R; Pickrell WO; Howell OW;
    Ann Neurol; 2024 Mar; 95(3):471-486. PubMed ID: 38061895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of Multiple sclerosis and its clinical and demographic characteristics in Kurdish populations in western Iran (2020).
    Razazian N; Eskandarieh S; Siabani S; Afshari D; Sahraian MA; Khezri O; Rezaei M; Fakhri N
    Mult Scler Relat Disord; 2022 Jan; 57():103441. PubMed ID: 34896874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology of familial multiple sclerosis in Iran: a national registry-based study.
    Salehi Z; Almasi-Hashiani A; Sahraian MA; Ashtari F; Baghbanian SM; Razazian N; Moghadasi AN; Bayati A; Azimi AR; Beladimoghadam N; Harirchian MH; Poursadeghfard M; Navardi S; Shirkoohi R; Heidari H; Ghaffari M; Eskandarieh S
    BMC Neurol; 2022 Mar; 22(1):76. PubMed ID: 35248009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and radiologic differences between early onset, late onset, and very late onset adult multiple sclerosis.
    Palathinkara M; Razzak AN; Ababneh OE; Cairns D; Obeidat AZ
    Mult Scler Relat Disord; 2023 Dec; 80():105132. PubMed ID: 37951095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis in the elderly: a retrospective cohort study.
    Zinganell A; Göbel G; Berek K; Hofer B; Asenbaum-Nan S; Barang M; Böck K; Bsteh C; Bsteh G; Eger S; Eggers C; Fertl E; Joldic D; Khalil M; Langenscheidt D; Komposch M; Kornek B; Kraus J; Krendl R; Rauschka H; Sellner J; Auer M; Hegen H; Pauli FD; Deisenhammer F
    J Neurol; 2024 Feb; 271(2):674-687. PubMed ID: 37855871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late onset multiple sclerosis: Is it really late onset?
    Roohani P; Emiru T; Carpenter A; Luzzio C; Freeman J; Scarberry S; Beaver G; Davidson L; Parry G
    Mult Scler Relat Disord; 2014 Jul; 3(4):444-9. PubMed ID: 25877055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple sclerosis: report on 200 cases from Iran.
    Kalanie H; Gharagozli K; Kalanie AR
    Mult Scler; 2003 Feb; 9(1):36-8. PubMed ID: 12617266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late onset multiple sclerosis.
    Arias M; Dapena D; Arias-Rivas S; Costa E; López A; Prieto JM; Corredera E
    Neurologia; 2011 Jun; 26(5):291-6. PubMed ID: 21163234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple Sclerosis Progression and Relapse Activity in Children.
    Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late onset multiple sclerosis - multiparametric MRI characteristics.
    Jasek Ł; Śmigielski J; Siger M
    Neurol Neurochir Pol; 2020; 54(3):265-271. PubMed ID: 32368786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.
    Shirani A; Zhao Y; Petkau J; Gustafson P; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Biomed Res Int; 2015; 2015():451912. PubMed ID: 25922836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling the natural history of primary progressive multiple sclerosis.
    Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.